Interleukin-1β genotype and circulating levels in cancer patients: Metastatic status and pain perception

Clinical Biochemistry

Volumn 47, Issue 13-14, 2014, Pages 1209-1213

  Oliveira, Ana ^a,b,c   Dinis Oliveira, Ricardo J ^a,c,d,e   Nogueira, Augusto ^b   Gonçalves, Ferraz ^b   Silva, Paula ^b   Vieira, Cláudia ^b   Silvestre, Ricardo ^c   Carvalho, Félix ^a   Medeiros, Rui ^a,b,f,g  

^a UNIVERSITY OF PORTO   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^d University of Porto   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^g LPCC Portuguese League Against Cancer Regional Centre of the North   (Portugal)

Author keywords

3954C>T; Cancer related pain; Interleukin 1; Metastatic disease; Polymorphisms

Indexed keywords

IL1A PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

BLOOD; CAUCASIAN; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; METASTASIS; MIDDLE AGED; NEOPLASM; NOCICEPTION; PAIN; PHYSIOLOGY;

EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PAIN; PAIN PERCEPTION; POLYMORPHISM, GENETIC;

EID: 84899467319     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.04.009     Document Type: Article

References (46)

1. WHO Cancer pain relief 1996, World Health Organisation, Geneva. 2nd ed.
2. Shi Q., Cleeland C., Klepstad P., Miaskowski C., Pedersen N. Biological pathways and genetic variables involved in pain. Qual Life Res 2010, 19:1407-1417.
3. Oliveira A., Dinis-Oliveira R., Nogueira A., Azevedo A., Gonçalves F., Silva P., et al. Genetic profile and cancer-related pain: a tale from two outlier cases with bone metastatic disease. Pain Med 2014, 15:710-712.
4. Hutchinson M.R., Coats B.D., Lewis S.S., Zhang Y., Sprunger D.B., Rezvani N., et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008, 22:1178-1189.
5. Kawasaki Y., Xu Z.Z., Wang X., Park J.Y., Zhuang Z.Y., Tan P.H., et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14:331-336.
6. Albulescu R., Codrici E., Popescu I.D., Mihai S., Necula L.G., Petrescu D., et al. Cytokine patterns in brain tumour progression. Mediators Inflamm 2013, 2013:7.
7. Gabay E., Wolf G., Shavit Y., Yirmiya R., Tal M. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain 2011, 15:242-248.
8. Watkins L.R., Maier S.F. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002, 82:981-1011.
9. Falchi M., Ferrara F., Gharib C., Dib B. Hyperalgesic effect of intrathecally administered interleukin-1 in rats. Drugs Exp Clin Res 2001, 27:97-101.
10. Mika J., Korostynski M., Kaminska D., Wawrzczak-Bargiela A., Osikowicz M., Makuch W., et al. Interleukin-1 alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain 2008, 138:587-597.
11. Shavit Y., Wolf G., Goshen I., Livshits D., Yirmiya R. Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain 2005, 115:50-59.
12. Mika J., Zychowska M., Popiolek-Barczyk K., Rojewska E., Przewlocka B. Importance of glial activation in neuropathic pain. Eur J Pharmacol 2013, 716:106-119.
13. Qian N., Chen X., Han S., Qiang F., Jin G., Zhou X., et al. Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women. J Cancer Res Clin Oncol 2010, 136:709-716.
14. Lacruz-Guzman D., Torres-Moreno D., Pedrero F., Romero-Cara P., Garcia-Tercero I., Trujillo-Santos J., et al. Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis. Eur J Clin Pharmacol 2013, 69:431-438.
15. Yilmaz I.A., Ozge A., Erdal M.E., Edgunlu T.G., Cakmak S.E., Yalin O.O. Cytokine polymorphism in patients with migraine: some suggestive clues of migraine and inflammation. Pain Med 2010, 11:492-497.
16. Wu X., Kondragunta V., Kornman K.S., Wang H.Y., Duff G.W., Renner J.B., et al. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage 2013, 21:930-938.
17. Lozano-Ondoua A.N., Symons-Liguori A.M., Vanderah T.W. Cancer-induced bone pain: mechanisms and models. Neurosci Lett 2013, 25. [00722-2].
18. Zabaleta J., Camargo M.C., Piazuelo M.B., Fontham E., Schneider B.G., Sicinschi L.A., et al. Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol 2006, 101:163-171.
19. Cepeda M., Etropolski M., Weinstein R., Fife D., Boston R., Matcho A. Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States. BMC Palliat Care 2010, 9:14.
20. Klepstad P., Loge J.H., Borchgrevink P.C., Mendoza T.R., Cleeland C.S., Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 2002, 24:517-525.
21. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
22. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
23. Gordon A., Kiss-Toth E., Stockley I., Eastell R., Wilkinson J.M. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum 2008, 58:3157-3165.
24. de Oliveira C.M., Sakata R.K., Issy A.M., Gerola L.R., Salomao R. Cytokines and pain. Rev Bras Anestesiol 2011, 61:255-259. [60-5, 137-42].
25. Copray J.C.V.M., Mantingh I., Brouwer N., Biber K., Küst B.M., Liem R.S.B., et al. Expression of interleukin-1 beta in rat dorsal root ganglia. J Neuroimmunol 2001, 118:203-211.
26. Cunha T.M., Verri W.A., Fukada S.Y., Guerrero A.T.G., Santodomingo-Garzón T., et al. TNF-α and IL-1β mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor. Eur J Pharmacol 2007, 573:221-229.
27. Buvanendran A., Kroin J.S., Berger R.A., Hallab N.J., Saha C., Negrescu C., et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology 2006, 104:403-410.
28. Burada F., Dumitrescu T., Nicoli R., Ciurea M.E., Angelescu C., Mixich F., et al. IL-1RN +2018 T>C polymorphism is correlated with colorectal cancer. Mol Biol Rep 2013, 40:2851-2857.
29. Paz Aparicio J., Fernandez Bances I., Lopez-Anglada Fernandez E., Montes A.H., Paz Aparicio A., Pena Vazquez J., et al. The IL-1beta (+3953 T/C) gene polymorphism associates to symptomatic lumbar disc herniation. Eur Spine J 2011, 20:383-389.
30. Sung C.-S., Wen Z.-H., Chang W.-K., Ho S.-T., Tsai S.-K., Chang Y.-C., et al. Intrathecal interleukin-1β administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res 2004, 1015:145-153.
31. Sweitzer S., Martin D., DeLeo J.A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103:529-539.
32. Cimaz R., Cazalis M.A., Reynaud C., Gerloni V., Zulian F., Biggioggero M., et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 2007, 66:900-904.
33. Solovieva S., Kamarainen O.P., Hirvonen A., Hamalainen S., Laitala M., Vehmas T., et al. Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol 2009, 36:1977-1986.
34. Bessler H., Shavit Y., Mayburd E., Smirnov G., Beilin B. Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist. Neurosci Lett 2006, 404:154-158.
35. Tolusso B., Pietrapertosa D., Morelli A., De Santis M., Gremese E., Farina G., et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006, 7:683-695.
36. Santtila S., Savinainen K., Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998, 47:195-198.
37. Eklund C., Jahan F., Pessi T., Lehtimaki T., Hurme M. Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw 2003, 14:168-171.
38. Maruyama Y., Nordfors L., Stenvinkel P., Heimburger O., Barany P., Pecoits-Filho R., et al. Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. Blood Purif 2005, 23:384-393.
39. Liu J., Zhai X., Jin G., Hu Z., Wang S., Wang X., et al. Functional variants in the promoter of interleukin-1beta are associated with an increased risk of breast cancer: a case-control analysis in a Chinese population. Int J Cancer 2006, 118:2554-2558.
40. Liu Q., Russell M.R., Shahriari K., Jernigan D.L., Lioni M.I., Garcia F.U., et al. Interleukin-1beta promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res 2013, 73:3297-3305.
41. Eiro N., Gonzalez L., Gonzalez L.O., Fernandez-Garcia B., Lamelas M.L., Marin L., et al. Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One 2012, 7:e49047.
42. Vangsted A.J., Nielsen K.R., Klausen T.W., Haukaas E., Tjonneland A., Vogel U. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma. Br J Haematol 2012, 158:515-518.
43. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol 2002, 169:469-475.
44. Berger P., McConnell J.P., Nunn M., Kornman K.S., Sorrell J., Stephenson K., et al. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 2002, 17:171-174.
45. Sigurdson A.J., Bhatti P., Doody M.M., Hauptmann M., Bowen L., Simon S.L., et al. Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists. Cancer Epidemiol Biomarkers Prev 2007, 16:2000-2007.
46. Crusius J.B., Canzian F., Capella G., Pena A.S., Pera G., Sala N., et al. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol 2008, 19:1894-1902.